RATIONALE AND OBJECTIVES: Conflict procedures are used to study mechanisms underlying the anxiolytic effects of benzodiazepines (BZs). We established a conflict procedure with rhesus monkeys in order to examine the role of GABAA receptors in the anxiolytic-like effects of BZs. METHODS: Four rhesus monkeys responded under a two-component multiple schedule in which responding was maintained under a fixed-ratio schedule of food delivery in the absence (non-suppressed responding) and presence (suppressed responding) of response-contingent electric shock. RESULTS: Conventional BZs (alprazolam, flunitrazepam, clonazepam, nitrazepam, lorazepam, bromazepam, diazepam, flurazepam, clorazepate, chlordiazepoxide) engendered increases in the average rates of suppressed responding at low to intermediate doses and decreased the average rates of non-suppressed responding at higher doses. Positive correlations were observed when the therapeutic potencies of BZs in humans were compared with potencies to increase the rates of suppressed responding (R2=0.83) or decrease the rates of non-suppressed responding (R2=0.60). The 5-HT1A agonist buspirone increased the rates of suppressed responding, although the effects were modest, whereas the opioid morphine lacked anti-conflict effects. The BZ antagonist flumazenil also modestly increased the rates of suppressed responding. A relatively low dose of flumazenil enhanced, while a high dose blocked, alprazolam's anti-conflict effects. Compounds selective for alpha1 subunit-containing GABAA receptors (zolpidem, zaleplon, CL218,872) engendered relatively weak increases in the rates of suppressed responding. CONCLUSIONS: A rhesus monkey conflict procedure was established with predictive validity for therapeutic doses in people and provided evidence that anxiolytic-like effects of BZs can occur with relatively low intrinsic efficacy at GABAA receptors and are reduced by alpha1GABAA receptor selectivity.
RATIONALE AND OBJECTIVES: Conflict procedures are used to study mechanisms underlying the anxiolytic effects of benzodiazepines (BZs). We established a conflict procedure with rhesus monkeys in order to examine the role of GABAA receptors in the anxiolytic-like effects of BZs. METHODS: Four rhesus monkeys responded under a two-component multiple schedule in which responding was maintained under a fixed-ratio schedule of food delivery in the absence (non-suppressed responding) and presence (suppressed responding) of response-contingent electric shock. RESULTS: Conventional BZs (alprazolam, flunitrazepam, clonazepam, nitrazepam, lorazepam, bromazepam, diazepam, flurazepam, clorazepate, chlordiazepoxide) engendered increases in the average rates of suppressed responding at low to intermediate doses and decreased the average rates of non-suppressed responding at higher doses. Positive correlations were observed when the therapeutic potencies of BZs in humans were compared with potencies to increase the rates of suppressed responding (R2=0.83) or decrease the rates of non-suppressed responding (R2=0.60). The 5-HT1A agonist buspirone increased the rates of suppressed responding, although the effects were modest, whereas the opioid morphine lacked anti-conflict effects. The BZ antagonist flumazenil also modestly increased the rates of suppressed responding. A relatively low dose of flumazenil enhanced, while a high dose blocked, alprazolam's anti-conflict effects. Compounds selective for alpha1 subunit-containing GABAA receptors (zolpidem, zaleplon, CL218,872) engendered relatively weak increases in the rates of suppressed responding. CONCLUSIONS: A rhesus monkey conflict procedure was established with predictive validity for therapeutic doses in people and provided evidence that anxiolytic-like effects of BZs can occur with relatively low intrinsic efficacy at GABAA receptors and are reduced by alpha1GABAA receptor selectivity.
Authors: Stephanie C Licata; Donna M Platt; James M Cook; P V V Srirama Sarma; Guy Griebel; James K Rowlett Journal: J Pharmacol Exp Ther Date: 2005-02-01 Impact factor: 4.030
Authors: A Lippa; P Czobor; J Stark; B Beer; E Kostakis; M Gravielle; S Bandyopadhyay; S J Russek; T T Gibbs; D H Farb; P Skolnick Journal: Proc Natl Acad Sci U S A Date: 2005-05-03 Impact factor: 11.205
Authors: James K Rowlett; Donna M Platt; Snjezana Lelas; John R Atack; Gerard R Dawson Journal: Proc Natl Acad Sci U S A Date: 2005-01-11 Impact factor: 11.205
Authors: F Crestani; R Keist; J-M Fritschy; D Benke; K Vogt; L Prut; H Blüthmann; H Möhler; U Rudolph Journal: Proc Natl Acad Sci U S A Date: 2002-06-25 Impact factor: 11.205
Authors: Bradford D Fischer; Stephanie C Licata; Rahul V Edwankar; Zhi-Jian Wang; Shengming Huang; Xiaohui He; Jianming Yu; Hao Zhou; Edward M Johnson; James M Cook; Roman Furtmüller; Joachim Ramerstorfer; Werner Sieghart; Bryan L Roth; Samarpan Majumder; James K Rowlett Journal: Neuropharmacology Date: 2010-08-18 Impact factor: 5.250
Authors: Bradford D Fischer; John R Atack; Donna M Platt; David S Reynolds; Gerard R Dawson; James K Rowlett Journal: Psychopharmacology (Berl) Date: 2010-12-30 Impact factor: 4.530
Authors: Christopher A Podlesnik; Mei-Chuan Ko; Gail Winger; Jürgen Wichmann; Eric P Prinssen; James H Woods Journal: Psychopharmacology (Berl) Date: 2010-09-18 Impact factor: 4.530
Authors: Angela N Duke; Zhiqiang Meng; Donna M Platt; John R Atack; Gerard R Dawson; David S Reynolds; V V N Phani Babu Tiruveedhula; Guanguan Li; Michael Rajesh Stephen; Werner Sieghart; James M Cook; James K Rowlett Journal: J Pharmacol Exp Ther Date: 2018-05-02 Impact factor: 4.030
Authors: Stephanie C Licata; Donna M Platt; Daniela Rüedi-Bettschen; John R Atack; Gerard R Dawson; Michael L Van Linn; James M Cook; James K Rowlett Journal: Neuropharmacology Date: 2009-10-22 Impact factor: 5.250